13 results on '"Juliusson, Gunnar"'
Search Results
2. Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
- Author
-
Lazarevic VL, Hägglund H, Remberger M, Wahlin A, Hallböök H, Juliusson G, Kimby E, Malm C, Omar H, and Johansson JE
- Subjects
- Adult, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Lymphoma, Follicular pathology, Male, Middle Aged, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local therapy, Prognosis, Risk Factors, Survival Rate, Sweden, Transplantation, Autologous, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Follicular mortality, Lymphoma, Follicular therapy, Stem Cell Transplantation, Survivors
- Published
- 2011
- Full Text
- View/download PDF
3. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
- Author
-
Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, and Wisløff F
- Subjects
- Aged, Aged, 80 and over, Bone Density Conservation Agents adverse effects, Bone Diseases diagnostic imaging, Bone Diseases etiology, Bone Diseases mortality, Diphosphonates adverse effects, Double-Blind Method, Female, Humans, Infusions, Intravenous, Jaw Diseases chemically induced, Kaplan-Meier Estimate, Male, Middle Aged, Multiple Myeloma complications, Multiple Myeloma diagnosis, Multiple Myeloma mortality, Osteonecrosis chemically induced, Pamidronate, Proportional Hazards Models, Radiography, Risk Assessment, Risk Factors, Scandinavian and Nordic Countries, Time Factors, Transplantation, Autologous, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Density Conservation Agents administration & dosage, Bone Diseases prevention & control, Diphosphonates administration & dosage, Multiple Myeloma therapy, Quality of Life, Stem Cell Transplantation
- Abstract
Background: Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma., Methods: This double-blind, randomised, phase 3 trial was undertaken at 37 clinics in Denmark, Norway, and Sweden. Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years. Randomisation was done by use of a central, computerised minimisation system. Primary outcome was physical function after 12 months estimated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire (scale 0-100). All patients who returned questionnaires at 12 months and were still on study treatment were included in the analysis of the primary endpoint. This study is registered with ClinicalTrials.gov, number NCT00376883., Findings: From January, 2001, until August, 2005, 504 patients were randomly assigned to pamidronate 30 mg or 90 mg (252 in each group). 157 patients in the 90 mg group and 156 in the 30 mg group were included in the primary analysis. Mean physical function at 12 months was 66 points (95% CI 62·9-70·0) in the 90 mg group and 68 points (64·6-71·4) in the 30 mg group (95% CI of difference -6·6 to 3·3; p=0·52). Median time to first skeletal-related event in patients who had such an event was 9·2 months (8·1-10·7) in the 90 mg group and 10·2 months (7·3-14·0) in the 30 mg group (p=0·63). In a retrospective analysis, eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group., Interpretation: Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma., Funding: Nordic Cancer Union and Novartis Healthcare., (Copyright © 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
4. Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial.
- Author
-
Jädersten, Martin, Lilienthal, Ingrid, Tsesmetzis, Nikolaos, Lourda, Magda, Bengtzén, Sofia, Bohlin, Anna, Arnroth, Cornelia, Erkers, Tom, Seashore‐Ludlow, Brinton, Giraud, Géraldine, Barkhordar, Giti S., Tao, Sijia, Fogelstrand, Linda, Saft, Leonie, Östling, Päivi, Schinazi, Raymond F., Kim, Baek, Schaller, Torsten, Juliusson, Gunnar, and Deneberg, Stefan
- Subjects
ACUTE myeloid leukemia ,HYDROXYUREA ,STEM cell transplantation ,POLYMERASE chain reaction ,DIAGNOSIS ,FEBRILE neutropenia - Abstract
Background: Treatment of newly diagnosed acute myeloid leukaemia (AML) is based on combination chemotherapy with cytarabine (ara‐C) and anthracyclines. Five‐year overall survival is below 30%, which has partly been attributed to cytarabine resistance. Preclinical data suggest that the addition of hydroxyurea potentiates cytarabine efficacy by increasing ara‐C triphosphate (ara‐CTP) levels through targeted inhibition of SAMHD1. Objectives: In this phase 1 trial, we evaluated the feasibility, safety and efficacy of the addition of hydroxyurea to standard chemotherapy with cytarabine/daunorubicin in newly diagnosed AML patients. Methods: Nine patients were enrolled and received at least two courses of ara‐C (1 g/m2/2 h b.i.d. d1‐5, i.e., a total of 10 g/m2 per course), hydroxyurea (1–2 g d1‐5) and daunorubicin (60 mg/m2 d1‐3). The primary endpoint was safety; secondary endpoints were complete remission rate and measurable residual disease (MRD). Additionally, pharmacokinetic studies of ara‐CTP and exvivo drug sensitivity assays were performed. Results: The most common grade 3‐4 toxicity was febrile neutropenia (100%). No unexpected toxicities were observed. Pharmacokinetic analyses showed a significant increase in median ara‐CTP levels (1.5‐fold; p = 0.04) in patients receiving doses of 1 g hydroxyurea. Ex vivo, diagnostic leukaemic bone marrow blasts from study patients were significantly sensitised to ara‐C by a median factor of 2.1 (p = 0.0047). All nine patients (100%) achieved complete remission, and all eight (100%) with validated MRD measurements (flow cytometry or real‐time quantitative polymerase chain reaction [RT‐qPCR]) had an MRD level <0.1% after two cycles of chemotherapy. Treatment was well‐tolerated, and median time to neutrophil recovery >1.0 × 109/L and to platelet recovery >50 × 109/L after the start of cycle 1 was 19 days and 22 days, respectively. Six of nine patients underwent allogeneic haematopoietic stem‐cell transplantation (allo‐HSCT). With a median follow‐up of 18.0 (range 14.9–20.5) months, one patient with adverse risk not fit for HSCT experienced a relapse after 11.9 months but is now in second complete remission. Conclusion: Targeted inhibition of SAMHD1 by the addition of hydroxyurea to conventional AML therapy is safe and appears efficacious within the limitations of the small phase 1 patient cohort. These results need to be corroborated in a larger study. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
- Author
-
Tettero, Jesse M., Al-Badri, Waleed K. W., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., van Elssen, Catharina H. M. J., Fischer, Thomas, Gjertsen, Bjorn T., van Gorkom, Gwendolyn N. Y., Gradowska, Patrycja, Greuter, Marjolein J. E., Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, and Ossenkoppele, Gert J.
- Subjects
ACUTE myeloid leukemia ,STEM cell transplantation ,STEM cell treatment ,INDUCTION chemotherapy ,COST control - Abstract
Measurable residual disease (MRD) measured using multiparameter flowcytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment for MRD-negative patients in the ELN-2017 intermediate risk group. Currently, measurement of MFC-MRD in bone marrow is used for clinical decision making after 2 cycles of induction chemotherapy. However, measurement after 1 cycle has also been shown to have prognostic value, so the optimal time point remains a question of debate. We assessed the independent prognostic value of MRD results at either time point and concordance between these for 273 AML patients treated within and according to the HOVON-SAKK 92, 102, 103 and 132 trials. Cumulative incidence of relapse, event free survival and overall survival were significantly better for MRD-negative (<0.1%) patients compared to MRD-positive patients after cycle 1 and cycle 2 (p ≤ 0.002, for all comparisons). A total of 196 patients (71.8%) were MRD-negative after cycle 1, of which the vast majority remained negative after cycle 2 (180 patients; 91.8%). In contrast, of the 77 MRD-positive patients after cycle 1, only 41 patients (53.2%) remained positive. A cost reduction of –€571,751 per 100 patients could be achieved by initiating the donor search based on the MRD-result after cycle 1. This equals to a 50.7% cost reduction compared to the current care strategy in which the donor search is initiated for all patients. These results show that MRD after cycle 1 has prognostic value and is highly concordant with MRD status after cycle 2. When MRD-MFC is used to guide consolidation treatment (allo vs non-allo) in intermediate risk patients, allogeneic donor search may be postponed or omitted after cycle 1. Since the majority of MRD-negative patients remain negative after cycle 2, this could safely reduce the number of allogeneic donor searches and reduce costs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Outcome and characteristics of non‐measurable myeloma: A cohort study with population‐based data from the Swedish Myeloma Registry.
- Author
-
Wålinder, Göran, Samuelsson, Jan, Näsman, Per, Hansson, Markus, Juliusson, Gunnar, Forsberg, Karin, Svensson, Ronald, Linder, Olle, Carlson, Kristina, Kristinsson, Sigurdur Y., Mellqvist, Ulf Henrik, Hveding Blimark, Cecilie, Turesson, Ingemar, and Nahi, Hareth
- Subjects
STEM cell transplantation ,COHORT analysis ,BLOOD proteins ,MULTIPLE myeloma ,URINE proteins - Abstract
Objective: We describe survival in patients with oligo‐ and non‐secretory multiple myeloma (MM). We refer to the whole group as non‐measurable MM and compare it with secretory MM. Methods: Oligo‐secretory MM was defined as M protein in serum <10 g/L and M protein in urine <200 measured as mg/day, mg/liter or mg/mmol creatinine. If patients had no M protein, they were defined as non‐secretory. The groups were also subdivided by Free Light Chains (SFLC) level and ratio. Results: Out of 4325 patients with symptomatic MM in the Swedish Myeloma Registry during 2008‐2016 eligible for the study, 389 patients (9%) had non‐measurable MM. Out of these, 253 patients (6%) had oligo‐secretory and 136 (3%) had non‐secretory MM. Median survival for secretory MM was 42.7 months, non‐measurable MM 40.2 months, oligo‐secretory MM 38.6 months, and non‐secretory MM 44.6 months. Difference in overall observed survival was non‐significant for all groups when compared with secretory MM. Within non‐secretory MM, stem cell transplantation (SCT), 95% being auto‐SCT, was significant for superior survival in multivariate analysis (HR 0.048. P =.0015). Conclusion: In this population‐based study, we found no difference in survival between oligo‐ or non‐secretory MM when compared with secretory MM. SCT appears to be important also for patients with non‐secretory disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Acute myeloid leukemia in the real world: why population-based registries are needed.
- Author
-
Juliusson, Gunnar, Lazarevic, Vladimir, Hörstedt, Ann-Sofi, Hagberg, Oskar, and Höglund, Martin
- Subjects
- *
ACUTE myeloid leukemia treatment , *MEDICAL sciences , *STEM cell transplantation , *MEDICAL registries , *ACUTE promyelocytic leukemia , *CANCER chemotherapy , *CANCER remission - Abstract
Population-based registries may provide data complementary to that from basic science and clinical intervention studies, all of which are essential for establishing recommendations for the management of patients in the real world. The same quality criteria apply for the evidence-based label, and both high representation and good data quality are crucial in registry studies. Registries with high coverage of the target population reduce the impact of selection on outcome and the subsequent problem with extrapolating data to nonstudied populations. Thus, data useful for clinical decision in situations not well covered by clinical studies can be provided. The potential clinical impact of data from population-based studies is exemplified with analyses from the Swedish Acute Leukemia Registry containing more than 3300 acute myeloid leukemia (AML) patients diagnosed between 1997 and 2006 with a median follow-up of 6.2 years on (1)the role of intensive combination chemotherapy for older patients with AML, (2) the impact of allogeneic stem cell transplantation on survival of younger patients with AML, and (3) the continuing problem with early deaths in acute promy-elocytic leukemia. We also present the first Web-based dynamic graph showing the complex interaction between age, performance status, the proportion of patients given intensive treatment, early death rate, complete remission rate, use of allogeneic transplants, and overall survival in AML (non-AML). [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia.
- Author
-
Juliusson, Gunnar, Karlsson, Karin, Lazarevic, Vladimir Lj, Wahlin, Anders, Brune, Mats, Antunovic, Petar, Derolf, Åsa, Hägglund, Hans, Karbach, Holger, Lehmann, Sören, Möllgård, Lars, Stockelberg, Dick, Hallböök, Helene, and Höglund, Martin
- Subjects
- *
CANCER research , *ACUTE myeloid leukemia , *LYMPHOBLASTIC leukemia , *STEM cell transplantation , *CANCER-related mortality , *CANCER relapse - Abstract
BACKGROUND: Allogeneic stem cell transplantation (alloSCT) reduces relapse rates in acute leukemia, but outcome is hampered by toxicity. Population-based data avoid patient selection and may therefore substitute for lack of randomized trials. METHODS: We evaluated alloSCT rates within the Swedish Acute Leukemia Registry, including 3899 adult patients diagnosed from 1997 through 2006 with a coverage of 98% and a median follow-up of 6.2 years. RESULTS: AlloSCT rates and survival decreased rapidly with age >55 years. The 8-year overall survival (OS) was 65% in patients <30 years and 38% in patients <60 years and was similar for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Among 1073 patients <60 years, alloSCT was performed in 42% and 49% of patients with AML and ALL, respectively. Two-thirds of the alloSCTs were performed in first complete remission, and half used unrelated donors, the same in AML and ALL. Regional differences in management and outcome were found: 60% of AML patients <40 years received alloSCT in all parts of Sweden, but two-thirds of AML patients 40-59 years had alloSCT in one region compared with one-third in other regions ( P<.001), with improved 8-year OS among all AML patients in this age cohort (51% vs 30%; P = .005). CONCLUSIONS: More Swedish AML patients received alloSCT, and long-term survival was better than in recently published large international studies, despite our lack of selection bias. There was no correlation between alloSCT rate and survival in ALL. In adult AML patients <60 years of age, a high alloSCT rate was associated with better long-term survival, but there was no such correlation in ALL. Cancer 2011;. © 2011 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Cyclophosphamide Plus Dexamethasone Is an Efficient Initial Treatment Before High-dose Melphalan and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma.
- Author
-
Mellqvist, Ulf-Henrik, Lenhoff, Stig, Johnsen, Hans E., Hjorth, Martin, Holmberg, Erik, Juliusson, Gunnar, Tangen, Jon Magnus, and Westin, Jan
- Subjects
CLINICAL trials ,STEM cell transplantation ,CELL transplantation ,TRANSPLANTATION of organs, tissues, etc. ,DOXORUBICIN - Abstract
The article focuses on a randomized trial conducted in 2001 by the Nordic Myeloma Study Group, in an attempt to bring a larger portion of patients to autologous stem cell transplantation (ASCT) more quickly. Under the trial, patients were randomized to receive either 3 cycles of vincristine, doxorubicin and dexamethasone (VAD) or 2 courses of cylcophosphamide plus dexamethasone. The study observed no significant difference in the proportion of patients undergoing ASCT.
- Published
- 2008
- Full Text
- View/download PDF
10. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
- Author
-
Lenhoff, Stig, Hjorth, Martin, Westin, Jan, Brinch, Lorentz, Bäckström, Bengt, Carlson, Kristina, Christiansen, Ilse, Dahl, Inger Marie, Gimsing, Peter, Hammerström, Jens, Johnsen, Hans E., Juliusson, Gunnar, Linder, Olle, Mellqvist, Ulf-Henrik, Nesthus, Ingerid, Nielsen, Johan Lanng, Tangen, Jon Magnus, and Turesson, Ingemar
- Subjects
BONE marrow cancer ,STEM cell transplantation ,THERAPEUTICS ,AUTOTRANSPLANTATION ,STEM cells ,HEMATOLOGY - Abstract
The value of intensive therapy, including autologous stem cell transplantation, in newly diagnosed myeloma patients >60 years is not clear. We evaluated the impact of age (<60 years vs. 60–64 years) on survival in a prospective, population-based setting and compared survival with conventionally treated historic controls. The prospective population comprised 452 patients registered between 1998 and 2000. Of these, 414 received intensive therapy. The historic population, derived from our most recent population-based study on conventional therapy, comprised 281 patients. Of these, 243 fulfilled our eligibility criteria for intensive therapy. For patients undergoing intensive therapy it was found that two factors, beta-2-microglobulin and age <60 years vs. 60–64 years, had independent prognostic impact on survival. However, compared with the historic controls a survival advantage was found both for patients <60 (median 66 months vs. 43 months, P < 0·001) and 60–64 years (median 50 months vs. 27 months; P = 0·001). We conclude that in a population-based setting higher age adversely influences outcome after intensive therapy. Our results indicate that intensive therapy prolongs survival also at age 60–64 years but with less superiority than in younger patients. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
11. Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
- Author
-
Lj Lazarevic, Vladimir, Hägglund, Hans, Remberger, Mats, Wahlin, Anders, Hallböök, Helene, Juliusson, Gunnar, Kimby, Eva, Malm, Claes, Omar, Hamdy, and Johansson, Jan-Erik
- Subjects
STEM cell transplantation ,LYMPHOMAS ,GRAFT versus host disease ,DISEASES in young adults ,LEUKEMIA treatment ,TUMOR treatment ,PATIENTS - Abstract
The article presents a study which examines the long-term survival of patients with follicular lymphoma (FL) in Sweden after allogeneic or syngeneic stem cell transplant. It says adult patients underwent allogeneic transplant associated with an immune-mediated graft-versus-lymphoma effect due to follicular lymphoma. It adds that the graft-versus-leukemia effect is not necessary, but suggests that tumor-free graft is significant for the success of follicular lymphoma transplant.
- Published
- 2011
- Full Text
- View/download PDF
12. Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting.
- Author
-
Nilsson, Christer, Hulegårdh, Erik, Garelius, Hege, Möllgård, Lars, Brune, Mats, Wahlin, Anders, Lenhoff, Stig, Frödin, Ulla, Remberger, Mats, Höglund, Martin, Juliusson, Gunnar, Stockelberg, Dick, and Lehmann, Sören
- Subjects
- *
LOG-rank test , *ACUTE myeloid leukemia , *STEM cell transplantation , *RITUXIMAB , *PROPENSITY score matching , *CELL transplantation , *MYELODYSPLASTIC syndromes - Abstract
• In a population-based setting, the proportion of patients with acute myeloid leukemia (AML) achieving complete remission who undergo allogeneic hematopoietic cell transplantation (HCT) is 23% of those with de novo AML, 28% of those with AML with an antecedent hematologic disorder, and 27% of those with therapy-related AML. • There is virtually no long-term survival in patients with secondary AML who do not undergo HCT. • Allogeneic HCT was superior to conventional chemotherapy in 3 different comparative analyses of patients with secondary AML. Secondary AML (s-AML), including AML with an antecedent hematologic disorder (AHD-AML) and therapy-related AML (t-AML), constitutes a large proportion of patients with AML and is considered to confer a dismal prognosis. The role of allogeneic hematopoietic cell transplantation (HCT) in patients with s-AML and the extent to which HCT is performed in these patients has been little studied to date. We used the population-based Swedish AML Registry comprising 3337 intensively treated adult patients over a 17-year period to study the role of HCT within the group of patients with s-AML as well as compared with patients with de novo AML. HCT was performed in 576 patients (22%) with de novo AML, in 74 patients (17%) with AHD-AML, and in 57 patients (20%) with t-AML. At 5 years after diagnosis, there were no survivors among patients with previous myeloproliferative neoplasms who did not undergo HCT, and corresponding survival for patients with antecedent myelodysplastic syndromes and t-AML was and 2% and 4%, respectively. HCT was compared with chemotherapy consolidation in s-AML using 3 models: (1) a 200-day landmark analysis, in which HCT was favorable compared with conventional consolidation (P =.04, log-rank test); (2) a multivariable Cox regression with HCT as a time-dependent variable, in which the hazard ratio for mortality was 0.73 (95% confidence interval, 0.64 to 0.83) for HCT and favored HCT in all subgroups; and (3) a propensity score matching analysis, in which the 5-year overall survival (OS) and relapse-free survival in patients with s-AML in first complete remission (CR1) was 48% and 43%, respectively, for patients undergoing HCT versus 20% and 21%, respectively, for those receiving chemotherapy consolidation (P =.01 and.02, respectively, log-rank test). Our observational data suggest that HCT improves survival and offers the only realistic curative treatment option in patients with s-AML. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. High-Dose Iodine-131-Metaiodobenzylguanidine with Haploidentical Stem Cell Transplantation and Posttransplant Immunotherapy in Children with Relapsed/Refractory Neuroblastoma
- Author
-
Toporski, Jacek, Garkavij, Michael, Tennvall, Jan, Øra, Ingrid, Gleisner, Katarina Sjögreen, Dykes, Josefina H., Lenhoff, Stig, Juliusson, Gunnar, Scheding, Stefan, Turkiewicz, Dominik, and Békássy, Albert N.
- Subjects
- *
GUANIDINES , *DRUG dosage , *STEM cell transplantation , *IMMUNOTHERAPY , *NEUROBLASTOMA , *TUMORS in children , *CANCER relapse , *DRUG efficacy , *GRAFT rejection , *THERAPEUTICS - Abstract
We evaluated the feasibility and efficacy of using high-dose iodine-131-metaiodobenzylguanidine (131I-MIBG) followed by reduced-intensity conditioning (RIC) and transplantation of T cell-depleted haploidentical peripheral blood stem cells (designated haplo-SCT) to treat relapsing/refractory neuroblastoma (RRNB). Five RRNB patients were enrolled: 4 with relapse (3 after autologous SCT) and 1 with induction therapy failure. The preparative regimen included high-dose 131I-MIBG on day –20, followed by fludarabine (Flu), thiotepa, and melphalan (Mel) from day –8 to –1. Granulocyte-colony stimulating factor (G-CSF)-mobilized, T cell-depleted haploidentical paternal stem cells were infused on day 0 together with cultured donor mesenchymal stem cells. A single dose of rituximab was given on day +1. After cessation of short immunosuppression (mycophenolate, OKT3), 4 children received donor lymphocyte infusion (DLI). 131I-MIBG infusion and RIC were well tolerated. All patients engrafted. No primary acute graft-versus-host disease (aGVHD) was observed. Four children developed aGVHD after DLI and were successfully treated. Analysis of immunologic recovery showed fast reappearance of potentially immunocompetent natural killer (NK) and T cells, which might have acted as effector cells responsible for the graft-versus-tumor (GVT) effect. Two children are alive and well, with no evidence of disease 40 and 42 months after transplantation. One patient experienced late progression with new bone lesions (sternum) 38 months after haplo-SCT, and is being treated with local irradiation and reinstituted DLI. One patient rejected the graft, was rescued with autologous backup, and died of progressive disease 5 months after transplantation. Another child relapsed 7 months after transplantation and died 5 months later. High-dose 131I-MIBG followed by RIC and haplo-SCT for RRNB is feasible and promising, because 2 of 5 children on that regimen achieved long-lasting remission. Further studies are needed to evaluate targeted therapy and immune-mediated tumor control in high-risk neuroblastoma. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.